The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates
In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms. The post The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates appeared first on GEN - Genetic Engineering and Biotechnology News .
Cindy Cheng, PhD, who leads the development of next-generation ADC and bioconjugation technologies at WuXi XDC, is set to discuss the evolution of dual-payload antibody-drug conjugates (dp-ADCs) in a GEN webinar. The event, scheduled for October 9, aims to shed light on how combining orthogonal or complementary payloads can overcome the constraints of single-drug ADCs.
Key aspects of the discussion include how payloads with different mechanisms can be combined to enhance efficacy, combat drug resistance, and boost drug safety. However, this complex strategy demands meticulous evaluation of safety and efficacy, synergy in payload pairing, and careful design of factors such as payload ratio, conjugation sites, linker properties, and release kinetics.
Cheng will delve into the biological underpinnings of mechanism-driven payload pairing, connecting these concepts with the intricate design of dp-ADCs. Additional topics will cover payload ratio, conjugation sites, the design of hydrophilic linkers, and strategies for controlled payload release.
Moreover, the webinar will address the non-clinical aspects of dp-ADC development, focusing on CMC (Chemistry, Manufacturing, and Control) strategies to ensure product quality when dealing with a complex molecule like dp-ADCs. The session will conclude with a live Q&A, allowing attendees to engage directly with the expert panelist.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
